Sara Miller
Concepts (697)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Wasps | 7 | 2023 | 15 | 2.980 |
Why?
| | Selection, Genetic | 6 | 2025 | 273 | 2.700 |
Why?
| | Cognition | 7 | 2025 | 1153 | 1.940 |
Why?
| | Biological Evolution | 6 | 2025 | 474 | 1.930 |
Why?
| | Smegmamorpha | 4 | 2019 | 6 | 1.890 |
Why?
| | Alcohol Drinking | 6 | 2025 | 828 | 1.850 |
Why?
| | Behavior, Animal | 4 | 2021 | 501 | 1.280 |
Why?
| | Coronavirus | 2 | 2020 | 47 | 1.260 |
Why?
| | Coronavirus Infections | 5 | 2020 | 364 | 1.180 |
Why?
| | Microscopy, Electron | 11 | 2022 | 443 | 1.170 |
Why?
| | Pneumonia, Viral | 4 | 2020 | 373 | 1.070 |
Why?
| | Memory Disorders | 3 | 2023 | 164 | 0.990 |
Why?
| | Pandemics | 7 | 2024 | 1639 | 0.920 |
Why?
| | Surgery, Computer-Assisted | 3 | 2018 | 101 | 0.920 |
Why?
| | Microscopy, Electron, Transmission | 6 | 2021 | 156 | 0.910 |
Why?
| | Substance-Related Disorders | 3 | 2023 | 1083 | 0.900 |
Why?
| | Genetic Fitness | 1 | 2025 | 59 | 0.900 |
Why?
| | Academic Performance | 1 | 2024 | 16 | 0.860 |
Why?
| | Optical Imaging | 3 | 2019 | 64 | 0.840 |
Why?
| | Diabetes, Gestational | 2 | 2025 | 318 | 0.820 |
Why?
| | Individuality | 1 | 2025 | 156 | 0.820 |
Why?
| | Amnesia, Anterograde | 1 | 2023 | 4 | 0.810 |
Why?
| | Prescription Drug Misuse | 1 | 2023 | 41 | 0.770 |
Why?
| | Placenta Accreta | 1 | 2022 | 27 | 0.760 |
Why?
| | Betacoronavirus | 4 | 2020 | 270 | 0.740 |
Why?
| | Archives | 1 | 2021 | 5 | 0.730 |
Why?
| | Ethology | 1 | 2021 | 2 | 0.720 |
Why?
| | Entomology | 1 | 2021 | 4 | 0.720 |
Why?
| | Cellular Structures | 1 | 2021 | 6 | 0.710 |
Why?
| | Data Curation | 1 | 2021 | 17 | 0.710 |
Why?
| | Life History Traits | 1 | 2021 | 15 | 0.700 |
Why?
| | Insecta | 1 | 2021 | 67 | 0.690 |
Why?
| | Behavior, Addictive | 1 | 2021 | 81 | 0.680 |
Why?
| | Humans | 90 | 2025 | 137585 | 0.680 |
Why?
| | Erythrocyte Transfusion | 1 | 2022 | 194 | 0.680 |
Why?
| | Gestational Age | 1 | 2024 | 910 | 0.680 |
Why?
| | Genetic Variation | 4 | 2024 | 991 | 0.680 |
Why?
| | Genome | 2 | 2022 | 300 | 0.670 |
Why?
| | Animal Communication | 1 | 2020 | 18 | 0.660 |
Why?
| | Infant, Premature | 2 | 2024 | 574 | 0.660 |
Why?
| | Ecology | 1 | 2021 | 118 | 0.650 |
Why?
| | Academic Success | 1 | 2019 | 29 | 0.630 |
Why?
| | Food Chain | 2 | 2019 | 41 | 0.620 |
Why?
| | Animals | 45 | 2025 | 36940 | 0.610 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 141 | 0.610 |
Why?
| | Perciformes | 1 | 2019 | 19 | 0.600 |
Why?
| | Animal Distribution | 1 | 2019 | 24 | 0.600 |
Why?
| | Hip | 1 | 2018 | 56 | 0.560 |
Why?
| | Sex Characteristics | 1 | 2023 | 762 | 0.560 |
Why?
| | Diagnostic Techniques, Ophthalmological | 1 | 2017 | 40 | 0.540 |
Why?
| | Optic Nerve Diseases | 1 | 2017 | 39 | 0.530 |
Why?
| | Photography | 1 | 2017 | 96 | 0.530 |
Why?
| | Optic Disk | 1 | 2017 | 45 | 0.520 |
Why?
| | Amputees | 1 | 2018 | 96 | 0.520 |
Why?
| | Caregivers | 2 | 2021 | 877 | 0.510 |
Why?
| | Stress, Psychological | 1 | 2025 | 1100 | 0.510 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1313 | 0.490 |
Why?
| | Child Development | 2 | 2019 | 475 | 0.480 |
Why?
| | Female | 46 | 2025 | 73304 | 0.480 |
Why?
| | Postural Balance | 1 | 2018 | 215 | 0.470 |
Why?
| | United States | 13 | 2025 | 14841 | 0.470 |
Why?
| | Students, Medical | 5 | 2021 | 348 | 0.470 |
Why?
| | Gait | 1 | 2018 | 296 | 0.460 |
Why?
| | Executive Function | 1 | 2019 | 451 | 0.450 |
Why?
| | Artificial Limbs | 1 | 2018 | 200 | 0.440 |
Why?
| | Glioblastoma | 1 | 2018 | 345 | 0.440 |
Why?
| | Ecosystem | 1 | 2019 | 596 | 0.440 |
Why?
| | Molecular Imaging | 3 | 2019 | 56 | 0.430 |
Why?
| | Phenotype | 5 | 2023 | 3196 | 0.430 |
Why?
| | Lower Extremity | 1 | 2018 | 427 | 0.430 |
Why?
| | Glaucoma | 1 | 2017 | 237 | 0.430 |
Why?
| | Genetics, Population | 3 | 2020 | 214 | 0.420 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2021 | 847 | 0.410 |
Why?
| | Male | 36 | 2025 | 67762 | 0.400 |
Why?
| | Neoplasms | 2 | 2021 | 2671 | 0.360 |
Why?
| | Catheter-Related Infections | 1 | 2012 | 92 | 0.360 |
Why?
| | General Surgery | 3 | 2018 | 173 | 0.360 |
Why?
| | Lung | 2 | 2022 | 4060 | 0.350 |
Why?
| | Education, Medical, Undergraduate | 3 | 2018 | 188 | 0.350 |
Why?
| | Bioterrorism | 3 | 2009 | 30 | 0.350 |
Why?
| | Genome, Insect | 2 | 2021 | 23 | 0.340 |
Why?
| | Infection Control | 1 | 2012 | 167 | 0.340 |
Why?
| | Catheterization, Central Venous | 1 | 2012 | 112 | 0.340 |
Why?
| | Comprehensive Health Care | 1 | 2010 | 24 | 0.340 |
Why?
| | National Health Programs | 2 | 2009 | 23 | 0.330 |
Why?
| | Public Policy | 1 | 2010 | 85 | 0.330 |
Why?
| | Endocytosis | 3 | 2022 | 172 | 0.320 |
Why?
| | Bacteremia | 1 | 2012 | 214 | 0.320 |
Why?
| | Social Behavior | 3 | 2023 | 287 | 0.320 |
Why?
| | Curriculum | 5 | 2021 | 992 | 0.320 |
Why?
| | Health Plan Implementation | 1 | 2010 | 142 | 0.320 |
Why?
| | Mitochondria, Heart | 2 | 2025 | 102 | 0.310 |
Why?
| | Brain Neoplasms | 1 | 2018 | 1238 | 0.300 |
Why?
| | Fluorescent Dyes | 4 | 2019 | 321 | 0.300 |
Why?
| | Dental Implantation, Endosseous | 1 | 2008 | 3 | 0.290 |
Why?
| | Dental Prosthesis, Implant-Supported | 1 | 2008 | 7 | 0.290 |
Why?
| | Intraoperative Care | 2 | 2019 | 52 | 0.290 |
Why?
| | Viruses | 1 | 2009 | 113 | 0.290 |
Why?
| | Career Choice | 3 | 2020 | 219 | 0.270 |
Why?
| | Virus Diseases | 1 | 2009 | 212 | 0.270 |
Why?
| | BK Virus | 3 | 2013 | 17 | 0.260 |
Why?
| | Myocytes, Cardiac | 2 | 2025 | 526 | 0.260 |
Why?
| | Tumor Virus Infections | 3 | 2013 | 49 | 0.260 |
Why?
| | Polyomavirus Infections | 3 | 2013 | 31 | 0.260 |
Why?
| | Child Behavior | 2 | 2019 | 248 | 0.250 |
Why?
| | Glucose Tolerance Test | 2 | 2025 | 366 | 0.250 |
Why?
| | Middle Aged | 13 | 2025 | 33479 | 0.250 |
Why?
| | Prospective Studies | 5 | 2023 | 7604 | 0.250 |
Why?
| | Infant, Newborn | 6 | 2024 | 6079 | 0.250 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2025 | 2 | 0.230 |
Why?
| | Blood Glucose | 3 | 2025 | 2186 | 0.230 |
Why?
| | Glutamate Carboxypeptidase II | 1 | 2025 | 6 | 0.230 |
Why?
| | Longitudinal Studies | 3 | 2024 | 2844 | 0.230 |
Why?
| | Pregnancy | 5 | 2025 | 6763 | 0.230 |
Why?
| | Carcinoma, Pancreatic Ductal | 2 | 2019 | 289 | 0.230 |
Why?
| | Antigens, Surface | 1 | 2025 | 154 | 0.220 |
Why?
| | Printing, Three-Dimensional | 1 | 2025 | 95 | 0.220 |
Why?
| | Adult | 16 | 2025 | 37929 | 0.220 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2025 | 224 | 0.220 |
Why?
| | Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 51 | 0.220 |
Why?
| | Apolipoprotein L1 | 1 | 2024 | 14 | 0.220 |
Why?
| | Autophagy | 4 | 2010 | 284 | 0.220 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2025 | 131 | 0.220 |
Why?
| | Spectroscopy, Near-Infrared | 3 | 2019 | 59 | 0.210 |
Why?
| | Virion | 2 | 2020 | 93 | 0.210 |
Why?
| | Cetuximab | 3 | 2019 | 98 | 0.210 |
Why?
| | Fibroblast Growth Factors | 1 | 2025 | 172 | 0.210 |
Why?
| | alpha-Synuclein | 1 | 2023 | 35 | 0.210 |
Why?
| | Haploidy | 1 | 2023 | 26 | 0.210 |
Why?
| | Variola virus | 1 | 2003 | 3 | 0.210 |
Why?
| | Transport Vesicles | 2 | 2018 | 20 | 0.210 |
Why?
| | Diploidy | 1 | 2023 | 19 | 0.210 |
Why?
| | Smallpox | 1 | 2003 | 9 | 0.210 |
Why?
| | Adenosine Triphosphatases | 3 | 2009 | 168 | 0.210 |
Why?
| | Substance Abuse, Intravenous | 1 | 2024 | 115 | 0.200 |
Why?
| | Surveys and Questionnaires | 4 | 2025 | 5778 | 0.200 |
Why?
| | Herpesviridae | 1 | 2003 | 23 | 0.200 |
Why?
| | Vaping | 1 | 2024 | 60 | 0.200 |
Why?
| | Virus Replication | 3 | 2023 | 483 | 0.200 |
Why?
| | Mass Screening | 2 | 2025 | 1287 | 0.200 |
Why?
| | Parents | 2 | 2024 | 1347 | 0.200 |
Why?
| | Disaster Planning | 2 | 2006 | 91 | 0.200 |
Why?
| | Health Care Surveys | 1 | 2025 | 565 | 0.200 |
Why?
| | Feeding Behavior | 2 | 2019 | 654 | 0.200 |
Why?
| | Obstetrics | 1 | 2025 | 163 | 0.200 |
Why?
| | Reproducibility of Results | 3 | 2021 | 3284 | 0.200 |
Why?
| | Guinea | 1 | 2022 | 1 | 0.200 |
Why?
| | Internal-External Control | 1 | 2023 | 71 | 0.200 |
Why?
| | Carrier Proteins | 2 | 2022 | 771 | 0.200 |
Why?
| | Aged | 8 | 2025 | 23961 | 0.200 |
Why?
| | Electronic Nicotine Delivery Systems | 1 | 2024 | 103 | 0.190 |
Why?
| | Ventricular Remodeling | 1 | 2025 | 266 | 0.190 |
Why?
| | Immunosenescence | 1 | 2022 | 5 | 0.190 |
Why?
| | Cell Cycle Proteins | 4 | 2018 | 617 | 0.190 |
Why?
| | Clinical Competence | 3 | 2020 | 1118 | 0.190 |
Why?
| | Retrospective Studies | 6 | 2023 | 15657 | 0.190 |
Why?
| | Nucleocapsid | 1 | 2022 | 19 | 0.190 |
Why?
| | Gene Frequency | 1 | 2023 | 521 | 0.190 |
Why?
| | Hysterectomy | 1 | 2022 | 129 | 0.180 |
Why?
| | Herpesviridae Infections | 1 | 2003 | 147 | 0.180 |
Why?
| | Nephrotic Syndrome | 1 | 2022 | 39 | 0.180 |
Why?
| | Muscle Proteins | 3 | 2008 | 231 | 0.180 |
Why?
| | Ethanol | 2 | 2023 | 608 | 0.180 |
Why?
| | Natural History | 1 | 2021 | 5 | 0.180 |
Why?
| | Killer Cells, Natural | 1 | 2025 | 449 | 0.180 |
Why?
| | Pediatric Obesity | 2 | 2019 | 601 | 0.180 |
Why?
| | Receptors, Odorant | 1 | 2021 | 32 | 0.180 |
Why?
| | Podocytes | 1 | 2022 | 69 | 0.180 |
Why?
| | Cesarean Section | 1 | 2022 | 184 | 0.180 |
Why?
| | Models, Biological | 5 | 2020 | 1783 | 0.170 |
Why?
| | Autopsy | 1 | 2021 | 95 | 0.170 |
Why?
| | Mice | 19 | 2025 | 17787 | 0.170 |
Why?
| | Nanospheres | 1 | 2020 | 1 | 0.170 |
Why?
| | Thorax | 1 | 2020 | 50 | 0.170 |
Why?
| | Cities | 1 | 2021 | 133 | 0.170 |
Why?
| | Myositis, Inclusion Body | 3 | 2010 | 11 | 0.170 |
Why?
| | Infant, Premature, Diseases | 1 | 2022 | 101 | 0.170 |
Why?
| | Hallucinogens | 1 | 2022 | 105 | 0.170 |
Why?
| | Lip | 1 | 2020 | 24 | 0.170 |
Why?
| | Epithelium | 2 | 2023 | 313 | 0.170 |
Why?
| | Mutation Rate | 1 | 2020 | 30 | 0.170 |
Why?
| | Pancreatic Neoplasms | 2 | 2019 | 938 | 0.170 |
Why?
| | Muscle, Skeletal | 5 | 2018 | 1724 | 0.170 |
Why?
| | Texas | 1 | 2021 | 244 | 0.170 |
Why?
| | Thrombocytopenia | 2 | 2020 | 200 | 0.170 |
Why?
| | Health Behavior | 2 | 2023 | 762 | 0.170 |
Why?
| | Biopsy | 3 | 2021 | 1129 | 0.170 |
Why?
| | Tendons | 1 | 2021 | 111 | 0.170 |
Why?
| | Multivariate Analysis | 1 | 2024 | 1509 | 0.170 |
Why?
| | Commission on Professional and Hospital Activities | 1 | 2020 | 4 | 0.160 |
Why?
| | Breeding | 1 | 2020 | 64 | 0.160 |
Why?
| | Interferon Regulatory Factors | 1 | 2020 | 39 | 0.160 |
Why?
| | Virus Assembly | 1 | 2020 | 78 | 0.160 |
Why?
| | Blood Transfusion | 1 | 2022 | 325 | 0.160 |
Why?
| | Kidney Transplantation | 3 | 2013 | 708 | 0.160 |
Why?
| | Cell Surface Extensions | 1 | 2019 | 13 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 146 | 0.160 |
Why?
| | Albumins | 1 | 2020 | 114 | 0.160 |
Why?
| | Educational Measurement | 2 | 2020 | 289 | 0.160 |
Why?
| | Seawater | 1 | 2019 | 31 | 0.160 |
Why?
| | Cleft Lip | 1 | 2020 | 52 | 0.160 |
Why?
| | Kidney Diseases | 1 | 2024 | 408 | 0.160 |
Why?
| | Fresh Water | 1 | 2019 | 57 | 0.160 |
Why?
| | Enteral Nutrition | 1 | 2022 | 202 | 0.160 |
Why?
| | Maternal Health Services | 1 | 2021 | 98 | 0.160 |
Why?
| | Transfection | 3 | 2018 | 945 | 0.160 |
Why?
| | Kidney Tubules, Proximal | 1 | 2020 | 128 | 0.160 |
Why?
| | China | 1 | 2020 | 217 | 0.160 |
Why?
| | Cleft Palate | 1 | 2020 | 68 | 0.160 |
Why?
| | Fibrinogen | 1 | 2020 | 168 | 0.160 |
Why?
| | Adult Stem Cells | 1 | 2019 | 40 | 0.160 |
Why?
| | Benchmarking | 1 | 2021 | 186 | 0.160 |
Why?
| | Cysts | 1 | 2020 | 113 | 0.160 |
Why?
| | Specialties, Surgical | 1 | 2020 | 75 | 0.160 |
Why?
| | Zebrafish | 3 | 2022 | 499 | 0.150 |
Why?
| | Satiety Response | 1 | 2019 | 10 | 0.150 |
Why?
| | Geography | 1 | 2019 | 200 | 0.150 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 190 | 0.150 |
Why?
| | Hyperphagia | 1 | 2019 | 34 | 0.150 |
Why?
| | Kingella kingae | 2 | 2009 | 12 | 0.150 |
Why?
| | Brain | 3 | 2021 | 2668 | 0.150 |
Why?
| | Species Specificity | 1 | 2020 | 585 | 0.150 |
Why?
| | Fimbriae, Bacterial | 2 | 2009 | 34 | 0.150 |
Why?
| | Staining and Labeling | 2 | 2012 | 150 | 0.150 |
Why?
| | Abnormalities, Multiple | 1 | 2020 | 189 | 0.150 |
Why?
| | Violence | 1 | 2021 | 266 | 0.150 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 32 | 0.150 |
Why?
| | Self Report | 1 | 2023 | 827 | 0.150 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2025 | 617 | 0.150 |
Why?
| | Lipid Metabolism | 1 | 2022 | 518 | 0.140 |
Why?
| | RNA, Viral | 2 | 2020 | 656 | 0.140 |
Why?
| | Exons | 2 | 2021 | 355 | 0.140 |
Why?
| | Hydrogels | 1 | 2025 | 678 | 0.140 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2031 | 0.140 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2018 | 56 | 0.140 |
Why?
| | Harassment, Non-Sexual | 1 | 2018 | 1 | 0.140 |
Why?
| | Child | 7 | 2024 | 21935 | 0.140 |
Why?
| | Indoles | 2 | 2019 | 412 | 0.140 |
Why?
| | Drug Approval | 1 | 2018 | 88 | 0.140 |
Why?
| | Family Relations | 1 | 2018 | 91 | 0.140 |
Why?
| | Biomechanical Phenomena | 2 | 2018 | 810 | 0.140 |
Why?
| | Endodeoxyribonucleases | 1 | 2018 | 72 | 0.140 |
Why?
| | Parkinson Disease | 1 | 2023 | 493 | 0.140 |
Why?
| | Bacterial Adhesion | 2 | 2008 | 100 | 0.140 |
Why?
| | Inclusion Bodies | 3 | 2023 | 28 | 0.140 |
Why?
| | Predatory Behavior | 2 | 2015 | 50 | 0.140 |
Why?
| | Nepal | 1 | 2017 | 30 | 0.140 |
Why?
| | Muscular Dystrophies, Limb-Girdle | 2 | 2008 | 6 | 0.140 |
Why?
| | Caveolae | 1 | 2017 | 18 | 0.140 |
Why?
| | Fishes | 2 | 2015 | 105 | 0.140 |
Why?
| | Notochord | 1 | 2017 | 14 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 394 | 0.140 |
Why?
| | Fractures, Bone | 1 | 2022 | 380 | 0.130 |
Why?
| | Lipids | 1 | 2022 | 672 | 0.130 |
Why?
| | Child, Preschool | 6 | 2024 | 11074 | 0.130 |
Why?
| | Multimodal Imaging | 1 | 2018 | 113 | 0.130 |
Why?
| | Memory, Short-Term | 1 | 2019 | 250 | 0.130 |
Why?
| | Prostatic Neoplasms | 1 | 2025 | 1043 | 0.130 |
Why?
| | Hematopoiesis | 1 | 2018 | 192 | 0.130 |
Why?
| | Family | 1 | 2021 | 671 | 0.130 |
Why?
| | Mycobacterium marinum | 1 | 2016 | 4 | 0.130 |
Why?
| | Gene Flow | 1 | 2017 | 86 | 0.130 |
Why?
| | Fluorescein Angiography | 1 | 2017 | 151 | 0.130 |
Why?
| | Observer Variation | 1 | 2017 | 343 | 0.130 |
Why?
| | Pancreatectomy | 1 | 2019 | 253 | 0.130 |
Why?
| | Young Adult | 5 | 2025 | 13209 | 0.130 |
Why?
| | Clinical Clerkship | 1 | 2018 | 101 | 0.130 |
Why?
| | Alcoholism | 1 | 2023 | 807 | 0.130 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2016 | 48 | 0.120 |
Why?
| | Lymph Nodes | 1 | 2019 | 491 | 0.120 |
Why?
| | British Columbia | 1 | 2015 | 21 | 0.120 |
Why?
| | Platelet-Derived Growth Factor | 2 | 2006 | 93 | 0.120 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1291 | 0.120 |
Why?
| | Learning | 1 | 2020 | 409 | 0.120 |
Why?
| | Hemorrhage | 1 | 2020 | 722 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 553 | 0.120 |
Why?
| | Cell Differentiation | 4 | 2021 | 1991 | 0.120 |
Why?
| | Intestinal Mucosa | 2 | 2019 | 623 | 0.120 |
Why?
| | Accidental Falls | 1 | 2018 | 196 | 0.120 |
Why?
| | Simulation Training | 1 | 2017 | 106 | 0.120 |
Why?
| | Mutation | 8 | 2018 | 3958 | 0.120 |
Why?
| | Cannabis | 1 | 2022 | 494 | 0.120 |
Why?
| | Interprofessional Relations | 1 | 2018 | 283 | 0.120 |
Why?
| | Mental Health | 1 | 2021 | 726 | 0.120 |
Why?
| | Oxidative Stress | 1 | 2022 | 1317 | 0.120 |
Why?
| | Aged, 80 and over | 2 | 2025 | 7635 | 0.120 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2016 | 140 | 0.110 |
Why?
| | Poverty | 1 | 2019 | 521 | 0.110 |
Why?
| | Parenting | 1 | 2018 | 310 | 0.110 |
Why?
| | Myocardial Ischemia | 1 | 2016 | 263 | 0.110 |
Why?
| | Urine | 2 | 2012 | 59 | 0.110 |
Why?
| | Insulin | 1 | 2025 | 2409 | 0.110 |
Why?
| | Nerve Fibers, Myelinated | 1 | 2014 | 47 | 0.110 |
Why?
| | Indians, North American | 2 | 2010 | 643 | 0.110 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2014 | 54 | 0.110 |
Why?
| | HIV Infections | 2 | 2024 | 2836 | 0.110 |
Why?
| | Motor Cortex | 1 | 2014 | 61 | 0.110 |
Why?
| | Kidney | 1 | 2021 | 1468 | 0.100 |
Why?
| | Acute Kidney Injury | 1 | 2021 | 815 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2057 | 0.100 |
Why?
| | Ubiquitin | 3 | 2009 | 70 | 0.100 |
Why?
| | Endoribonucleases | 1 | 2014 | 81 | 0.100 |
Why?
| | Adolescent Behavior | 1 | 2018 | 530 | 0.100 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2014 | 110 | 0.100 |
Why?
| | Fatty Acids | 1 | 2016 | 443 | 0.100 |
Why?
| | Sensitivity and Specificity | 1 | 2018 | 1946 | 0.100 |
Why?
| | DNA Methylation | 1 | 2018 | 643 | 0.100 |
Why?
| | Wound Healing | 3 | 2021 | 331 | 0.100 |
Why?
| | Mitochondria | 1 | 2019 | 948 | 0.100 |
Why?
| | Methylene Blue | 1 | 2012 | 24 | 0.100 |
Why?
| | Antisepsis | 1 | 2012 | 1 | 0.100 |
Why?
| | Risk Factors | 4 | 2024 | 10388 | 0.100 |
Why?
| | Internship and Residency | 2 | 2020 | 1147 | 0.100 |
Why?
| | Pelvic Pain | 1 | 2012 | 34 | 0.100 |
Why?
| | Chlorhexidine | 1 | 2012 | 24 | 0.100 |
Why?
| | Sleep | 1 | 2019 | 755 | 0.100 |
Why?
| | Heart | 1 | 2016 | 655 | 0.100 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2014 | 128 | 0.100 |
Why?
| | Molecular Motor Proteins | 1 | 2012 | 45 | 0.100 |
Why?
| | Endometriosis | 1 | 2012 | 51 | 0.090 |
Why?
| | Recovery of Function | 1 | 2016 | 653 | 0.090 |
Why?
| | Neural Stem Cells | 1 | 2014 | 156 | 0.090 |
Why?
| | Myelin Sheath | 1 | 2014 | 167 | 0.090 |
Why?
| | Cell Line | 7 | 2018 | 2847 | 0.090 |
Why?
| | Oligodendroglia | 1 | 2014 | 179 | 0.090 |
Why?
| | Equipment Contamination | 1 | 2012 | 67 | 0.090 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2019 | 2189 | 0.090 |
Why?
| | Mutation, Missense | 2 | 2010 | 341 | 0.090 |
Why?
| | Infant | 3 | 2022 | 9465 | 0.090 |
Why?
| | Tissue Engineering | 2 | 2025 | 423 | 0.090 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 630 | 0.090 |
Why?
| | Peptides | 4 | 2013 | 985 | 0.090 |
Why?
| | Myosin Heavy Chains | 1 | 2012 | 192 | 0.090 |
Why?
| | Oklahoma | 1 | 2010 | 12 | 0.090 |
Why?
| | Program Evaluation | 2 | 2017 | 898 | 0.090 |
Why?
| | Guam | 1 | 2010 | 14 | 0.090 |
Why?
| | Myocardium | 1 | 2016 | 1002 | 0.090 |
Why?
| | Receptors, Progesterone | 1 | 2013 | 350 | 0.090 |
Why?
| | Multienzyme Complexes | 1 | 2010 | 68 | 0.090 |
Why?
| | DNA, Viral | 1 | 2012 | 364 | 0.080 |
Why?
| | Microscopy, Immunoelectron | 2 | 2022 | 46 | 0.080 |
Why?
| | Mice, Transgenic | 5 | 2024 | 2167 | 0.080 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2013 | 252 | 0.080 |
Why?
| | Cell Line, Tumor | 5 | 2025 | 3412 | 0.080 |
Why?
| | Muscle Weakness | 2 | 2010 | 88 | 0.080 |
Why?
| | Fish Diseases | 1 | 2010 | 16 | 0.080 |
Why?
| | Knowledge | 2 | 2021 | 55 | 0.080 |
Why?
| | Arthrogryposis | 1 | 2010 | 8 | 0.080 |
Why?
| | Osteitis Deformans | 1 | 2009 | 7 | 0.080 |
Why?
| | Fluorescent Antibody Technique | 2 | 2022 | 390 | 0.080 |
Why?
| | Health Care Reform | 1 | 2010 | 107 | 0.080 |
Why?
| | RNA Polymerase Sigma 54 | 1 | 2009 | 3 | 0.080 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 255 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2253 | 0.080 |
Why?
| | Computer Simulation | 2 | 2018 | 978 | 0.080 |
Why?
| | Fimbriae Proteins | 1 | 2009 | 21 | 0.080 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1738 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2022 | 3556 | 0.080 |
Why?
| | Frontotemporal Dementia | 1 | 2009 | 57 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2025 | 4295 | 0.080 |
Why?
| | Luciferases | 1 | 2009 | 150 | 0.080 |
Why?
| | Norwalk virus | 1 | 2008 | 2 | 0.070 |
Why?
| | Macrophages | 1 | 2016 | 1547 | 0.070 |
Why?
| | Biological Assay | 1 | 2009 | 124 | 0.070 |
Why?
| | History, 21st Century | 1 | 2009 | 213 | 0.070 |
Why?
| | Dental Abutments | 1 | 2008 | 1 | 0.070 |
Why?
| | Denture, Partial, Immediate | 1 | 2008 | 2 | 0.070 |
Why?
| | Dental Prosthesis Design | 1 | 2008 | 4 | 0.070 |
Why?
| | Dental Restoration Failure | 1 | 2008 | 7 | 0.070 |
Why?
| | Gene Expression Regulation, Viral | 2 | 2014 | 95 | 0.070 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2008 | 43 | 0.070 |
Why?
| | Genes, Reporter | 1 | 2009 | 269 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2025 | 5757 | 0.070 |
Why?
| | Incisor | 1 | 2008 | 19 | 0.070 |
Why?
| | Haemophilus | 1 | 2008 | 7 | 0.070 |
Why?
| | Quadriceps Muscle | 1 | 2009 | 133 | 0.070 |
Why?
| | Fas Ligand Protein | 1 | 2008 | 60 | 0.070 |
Why?
| | Cyclic GMP-Dependent Protein Kinases | 1 | 2008 | 5 | 0.070 |
Why?
| | Transcriptome | 1 | 2014 | 971 | 0.070 |
Why?
| | Maxilla | 1 | 2008 | 38 | 0.070 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 52 | 0.070 |
Why?
| | History, 20th Century | 1 | 2009 | 325 | 0.070 |
Why?
| | Computer-Aided Design | 1 | 2008 | 43 | 0.070 |
Why?
| | Adhesins, Bacterial | 1 | 2008 | 40 | 0.070 |
Why?
| | Microscopy, Fluorescence | 2 | 2019 | 402 | 0.070 |
Why?
| | Models, Anatomic | 1 | 2008 | 93 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 69 | 0.070 |
Why?
| | Cell Membrane | 2 | 2016 | 738 | 0.070 |
Why?
| | Health Policy | 1 | 2010 | 388 | 0.070 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2008 | 136 | 0.070 |
Why?
| | Adenocarcinoma | 1 | 2013 | 940 | 0.060 |
Why?
| | Adolescent | 5 | 2025 | 21513 | 0.060 |
Why?
| | Molecular Sequence Data | 5 | 2010 | 2900 | 0.060 |
Why?
| | Myofibrils | 1 | 2006 | 50 | 0.060 |
Why?
| | Bacterial Proteins | 2 | 2009 | 879 | 0.060 |
Why?
| | Sentinel Surveillance | 1 | 2006 | 49 | 0.060 |
Why?
| | Bone Regeneration | 1 | 2006 | 26 | 0.060 |
Why?
| | Population Surveillance | 1 | 2009 | 482 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5472 | 0.060 |
Why?
| | Communicable Diseases, Emerging | 1 | 2006 | 36 | 0.060 |
Why?
| | Periodontitis | 1 | 2006 | 53 | 0.060 |
Why?
| | Follow-Up Studies | 4 | 2020 | 5131 | 0.060 |
Why?
| | Immune Tolerance | 1 | 2008 | 363 | 0.060 |
Why?
| | Cells, Cultured | 2 | 2025 | 4193 | 0.060 |
Why?
| | Antilymphocyte Serum | 2 | 2021 | 66 | 0.060 |
Why?
| | Cytoskeletal Proteins | 1 | 2006 | 158 | 0.060 |
Why?
| | Phosphoproteins | 1 | 2008 | 338 | 0.060 |
Why?
| | Periodontal Diseases | 1 | 2006 | 61 | 0.060 |
Why?
| | Rabbits | 2 | 2022 | 794 | 0.060 |
Why?
| | Gelatin | 1 | 2025 | 52 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2008 | 446 | 0.060 |
Why?
| | Binge Drinking | 1 | 2025 | 43 | 0.060 |
Why?
| | Ecological Momentary Assessment | 1 | 2025 | 36 | 0.060 |
Why?
| | Laboratories | 1 | 2006 | 113 | 0.060 |
Why?
| | Bioprinting | 1 | 2025 | 30 | 0.060 |
Why?
| | Neurons | 1 | 2014 | 1590 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3715 | 0.060 |
Why?
| | Methacrylates | 1 | 2025 | 117 | 0.060 |
Why?
| | Enterotoxins | 1 | 2004 | 88 | 0.060 |
Why?
| | Valosin Containing Protein | 3 | 2009 | 8 | 0.060 |
Why?
| | Interleukin-15 | 1 | 2025 | 98 | 0.060 |
Why?
| | Smoke-Free Policy | 1 | 2024 | 13 | 0.060 |
Why?
| | Nephritis | 1 | 2004 | 23 | 0.060 |
Why?
| | Rats | 3 | 2025 | 5647 | 0.060 |
Why?
| | Opportunistic Infections | 1 | 2004 | 46 | 0.050 |
Why?
| | Bacterial Toxins | 1 | 2004 | 106 | 0.050 |
Why?
| | Acridine Orange | 1 | 2004 | 4 | 0.050 |
Why?
| | Intestine, Large | 1 | 2004 | 14 | 0.050 |
Why?
| | Nucleocapsid Proteins | 1 | 2023 | 23 | 0.050 |
Why?
| | Risk Assessment | 2 | 2010 | 3457 | 0.050 |
Why?
| | Endothelial Cells | 2 | 2020 | 785 | 0.050 |
Why?
| | Disease Outbreaks | 2 | 2022 | 395 | 0.050 |
Why?
| | Plasmids | 2 | 2018 | 363 | 0.050 |
Why?
| | Virulence Factors | 1 | 2004 | 167 | 0.050 |
Why?
| | Dopaminergic Neurons | 1 | 2023 | 69 | 0.050 |
Why?
| | Inclusion Bodies, Viral | 1 | 2002 | 3 | 0.050 |
Why?
| | Glycolysis | 1 | 2025 | 321 | 0.050 |
Why?
| | Orthopoxvirus | 1 | 2002 | 3 | 0.050 |
Why?
| | Viral Structural Proteins | 1 | 2002 | 13 | 0.050 |
Why?
| | Adenine | 1 | 2025 | 271 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2004 | 200 | 0.050 |
Why?
| | Immunoblotting | 2 | 2016 | 308 | 0.050 |
Why?
| | Light | 1 | 2025 | 381 | 0.050 |
Why?
| | Gene Deletion | 2 | 2018 | 391 | 0.050 |
Why?
| | Rejuvenation | 1 | 2022 | 19 | 0.050 |
Why?
| | HIV-1 | 1 | 2008 | 864 | 0.050 |
Why?
| | Vero Cells | 1 | 2022 | 69 | 0.050 |
Why?
| | Epithelial Cells | 1 | 2008 | 1096 | 0.050 |
Why?
| | Fracture Healing | 1 | 2022 | 79 | 0.050 |
Why?
| | Trastuzumab | 1 | 2022 | 96 | 0.050 |
Why?
| | Ki-67 Antigen | 1 | 2022 | 112 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 872 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2021 | 76 | 0.050 |
Why?
| | Thymocytes | 1 | 2021 | 36 | 0.050 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2021 | 27 | 0.050 |
Why?
| | Gene Knockout Techniques | 1 | 2022 | 118 | 0.040 |
Why?
| | Intubation, Gastrointestinal | 1 | 2022 | 79 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2024 | 730 | 0.040 |
Why?
| | Biofilms | 1 | 2004 | 260 | 0.040 |
Why?
| | United Kingdom | 1 | 2022 | 318 | 0.040 |
Why?
| | Impulsive Behavior | 1 | 2022 | 150 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 10811 | 0.040 |
Why?
| | Transcription Factors | 1 | 2009 | 1719 | 0.040 |
Why?
| | Fasting | 1 | 2022 | 281 | 0.040 |
Why?
| | Belgium | 1 | 2020 | 13 | 0.040 |
Why?
| | Lymphocyte Activation | 1 | 2025 | 1142 | 0.040 |
Why?
| | Cooperative Behavior | 1 | 2023 | 451 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2021 | 109 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2025 | 674 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2022 | 125 | 0.040 |
Why?
| | Recombination, Genetic | 2 | 2017 | 204 | 0.040 |
Why?
| | Quinazolines | 1 | 2022 | 251 | 0.040 |
Why?
| | Tendon Injuries | 1 | 2021 | 68 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2021 | 310 | 0.040 |
Why?
| | Graft Rejection | 1 | 2004 | 624 | 0.040 |
Why?
| | Colorado | 1 | 2010 | 4565 | 0.040 |
Why?
| | Escherichia coli | 1 | 2004 | 815 | 0.040 |
Why?
| | Chloroquine | 2 | 2010 | 54 | 0.040 |
Why?
| | Endothelium | 1 | 2020 | 123 | 0.040 |
Why?
| | Myofibroblasts | 1 | 2021 | 127 | 0.040 |
Why?
| | Platelet Aggregation | 1 | 2020 | 103 | 0.040 |
Why?
| | Genetic Association Studies | 1 | 2022 | 377 | 0.040 |
Why?
| | Patient Care | 1 | 2021 | 111 | 0.040 |
Why?
| | Receptor, ErbB-2 | 1 | 2022 | 341 | 0.040 |
Why?
| | RNA Interference | 2 | 2013 | 469 | 0.040 |
Why?
| | Aggression | 1 | 2021 | 202 | 0.040 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2021 | 243 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 404 | 0.040 |
Why?
| | Education | 1 | 2020 | 108 | 0.040 |
Why?
| | Contraception | 1 | 2021 | 161 | 0.040 |
Why?
| | Tissue Embedding | 1 | 2018 | 4 | 0.040 |
Why?
| | Pinocytosis | 1 | 2018 | 11 | 0.040 |
Why?
| | Microtubule-Associated Proteins | 2 | 2010 | 196 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2022 | 622 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2025 | 922 | 0.040 |
Why?
| | Electricity | 1 | 2018 | 23 | 0.040 |
Why?
| | Zebrafish Proteins | 1 | 2022 | 288 | 0.040 |
Why?
| | Cell Culture Techniques | 1 | 2021 | 363 | 0.040 |
Why?
| | Mutation Accumulation | 1 | 2018 | 1 | 0.040 |
Why?
| | Clathrin | 1 | 2018 | 27 | 0.040 |
Why?
| | Digoxin | 1 | 2018 | 31 | 0.040 |
Why?
| | Viral Load | 2 | 2012 | 466 | 0.040 |
Why?
| | Hunger | 1 | 2019 | 45 | 0.040 |
Why?
| | Cultural Characteristics | 1 | 2018 | 67 | 0.040 |
Why?
| | Drosophila | 1 | 2019 | 154 | 0.040 |
Why?
| | GPI-Linked Proteins | 1 | 2018 | 73 | 0.040 |
Why?
| | Veins | 1 | 2018 | 63 | 0.040 |
Why?
| | Postpartum Period | 1 | 2021 | 340 | 0.040 |
Why?
| | Physician Assistants | 1 | 2020 | 94 | 0.040 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2018 | 108 | 0.040 |
Why?
| | Germ Cells | 1 | 2018 | 64 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 539 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2022 | 565 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2008 | 2691 | 0.030 |
Why?
| | Lymph Node Excision | 1 | 2019 | 171 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2025 | 3015 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2019 | 352 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2012 | 1062 | 0.030 |
Why?
| | Computer-Assisted Instruction | 1 | 2018 | 66 | 0.030 |
Why?
| | Glucose | 1 | 2022 | 1020 | 0.030 |
Why?
| | Biological Transport | 1 | 2018 | 418 | 0.030 |
Why?
| | Gene Transfer Techniques | 1 | 2018 | 170 | 0.030 |
Why?
| | Self Efficacy | 1 | 2021 | 396 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1325 | 0.030 |
Why?
| | Microtubules | 1 | 2019 | 279 | 0.030 |
Why?
| | Prognosis | 2 | 2018 | 4030 | 0.030 |
Why?
| | Muscle Fibers, Skeletal | 2 | 2009 | 218 | 0.030 |
Why?
| | Binding Sites | 1 | 2020 | 1303 | 0.030 |
Why?
| | Signal Transduction | 2 | 2025 | 5079 | 0.030 |
Why?
| | Schools, Medical | 1 | 2018 | 147 | 0.030 |
Why?
| | Faculty | 1 | 2018 | 147 | 0.030 |
Why?
| | Isolated Heart Preparation | 1 | 2016 | 6 | 0.030 |
Why?
| | Sarcolemma | 2 | 2007 | 43 | 0.030 |
Why?
| | Organizational Culture | 1 | 2018 | 148 | 0.030 |
Why?
| | Mutant Proteins | 2 | 2007 | 103 | 0.030 |
Why?
| | Gene Expression Regulation, Bacterial | 2 | 2009 | 328 | 0.030 |
Why?
| | Microfilament Proteins | 2 | 2008 | 133 | 0.030 |
Why?
| | Neutrophils | 1 | 2022 | 1238 | 0.030 |
Why?
| | L-Lactate Dehydrogenase | 1 | 2016 | 122 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-sis | 2 | 2006 | 39 | 0.030 |
Why?
| | Patient Safety | 1 | 2020 | 314 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2008 | 976 | 0.030 |
Why?
| | Granuloma | 1 | 2016 | 92 | 0.030 |
Why?
| | Cues | 1 | 2018 | 314 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2021 | 641 | 0.030 |
Why?
| | Eating | 1 | 2019 | 380 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 350 | 0.030 |
Why?
| | Energy Intake | 1 | 2019 | 485 | 0.030 |
Why?
| | California | 1 | 2017 | 431 | 0.030 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2021 | 1477 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 1079 | 0.030 |
Why?
| | ErbB Receptors | 1 | 2019 | 614 | 0.030 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2016 | 135 | 0.030 |
Why?
| | Collagen Type I | 2 | 2006 | 136 | 0.030 |
Why?
| | Necrosis | 1 | 2016 | 246 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2017 | 485 | 0.030 |
Why?
| | Placenta | 1 | 2021 | 750 | 0.030 |
Why?
| | Amino Acid Transport Systems, Basic | 1 | 2014 | 5 | 0.030 |
Why?
| | Focus Groups | 1 | 2018 | 522 | 0.030 |
Why?
| | Cadherins | 1 | 2016 | 206 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 956 | 0.030 |
Why?
| | Myocardial Contraction | 1 | 2016 | 341 | 0.030 |
Why?
| | Interviews as Topic | 1 | 2018 | 786 | 0.030 |
Why?
| | Thy-1 Antigens | 1 | 2014 | 12 | 0.030 |
Why?
| | Mentoring | 1 | 2017 | 149 | 0.030 |
Why?
| | Channelrhodopsins | 1 | 2014 | 16 | 0.030 |
Why?
| | Alleles | 1 | 2017 | 891 | 0.030 |
Why?
| | Activating Transcription Factor 6 | 1 | 2014 | 20 | 0.030 |
Why?
| | HeLa Cells | 2 | 2008 | 636 | 0.030 |
Why?
| | Corpus Callosum | 1 | 2014 | 71 | 0.030 |
Why?
| | Primates | 1 | 2014 | 126 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2014 | 298 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 1050 | 0.030 |
Why?
| | Emotions | 1 | 2019 | 548 | 0.030 |
Why?
| | Mycobacterium tuberculosis | 1 | 2016 | 314 | 0.030 |
Why?
| | Base Pairing | 1 | 2013 | 64 | 0.030 |
Why?
| | Blotting, Northern | 1 | 2013 | 201 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 72 | 0.030 |
Why?
| | Mitochondrial Membranes | 1 | 2013 | 39 | 0.030 |
Why?
| | Peritoneal Cavity | 1 | 2012 | 32 | 0.020 |
Why?
| | Nephritis, Hereditary | 1 | 2012 | 2 | 0.020 |
Why?
| | Cell Survival | 1 | 2016 | 1120 | 0.020 |
Why?
| | Cell Respiration | 1 | 2013 | 103 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1692 | 0.020 |
Why?
| | Apoptosis | 1 | 2022 | 2553 | 0.020 |
Why?
| | Recombinant Proteins | 2 | 2006 | 1353 | 0.020 |
Why?
| | Progestins | 1 | 2013 | 79 | 0.020 |
Why?
| | Cerebral Infarction | 1 | 2012 | 44 | 0.020 |
Why?
| | Microscopy, Electron, Scanning | 1 | 2012 | 201 | 0.020 |
Why?
| | RNA Splicing | 1 | 2014 | 269 | 0.020 |
Why?
| | Cell Lineage | 1 | 2014 | 350 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2021 | 2607 | 0.020 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2012 | 67 | 0.020 |
Why?
| | Dietary Supplements | 1 | 2016 | 561 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1459 | 0.020 |
Why?
| | Endoplasmic Reticulum | 1 | 2014 | 265 | 0.020 |
Why?
| | Protein Transport | 1 | 2013 | 445 | 0.020 |
Why?
| | Muscle Denervation | 1 | 2010 | 9 | 0.020 |
Why?
| | Colchicine | 1 | 2010 | 24 | 0.020 |
Why?
| | Tubulin Modulators | 1 | 2010 | 10 | 0.020 |
Why?
| | Vinblastine | 1 | 2010 | 71 | 0.020 |
Why?
| | Mitochondrial Proteins | 1 | 2013 | 257 | 0.020 |
Why?
| | Host-Pathogen Interactions | 1 | 2014 | 364 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1386 | 0.020 |
Why?
| | Hemorrhagic Septicemia, Viral | 1 | 2010 | 1 | 0.020 |
Why?
| | Mesomycetozoea | 1 | 2010 | 1 | 0.020 |
Why?
| | Mesomycetozoea Infections | 1 | 2010 | 1 | 0.020 |
Why?
| | Pacific Ocean | 1 | 2010 | 8 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 493 | 0.020 |
Why?
| | Ulcer | 1 | 2010 | 33 | 0.020 |
Why?
| | Calcium | 1 | 2016 | 1199 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 1329 | 0.020 |
Why?
| | Sequestosome-1 Protein | 1 | 2009 | 15 | 0.020 |
Why?
| | Genes, Dominant | 1 | 2010 | 96 | 0.020 |
Why?
| | Biomarkers | 1 | 2021 | 4149 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2013 | 739 | 0.020 |
Why?
| | Tissue Extracts | 1 | 2009 | 21 | 0.020 |
Why?
| | Population Dynamics | 1 | 2010 | 151 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 392 | 0.020 |
Why?
| | Motor Activity | 1 | 2014 | 718 | 0.020 |
Why?
| | Protein Structure, Quaternary | 1 | 2009 | 128 | 0.020 |
Why?
| | Protein Isoforms | 1 | 2010 | 404 | 0.020 |
Why?
| | Heat-Shock Proteins | 1 | 2009 | 143 | 0.020 |
Why?
| | Electrophoretic Mobility Shift Assay | 1 | 2009 | 86 | 0.020 |
Why?
| | Fibroblasts | 1 | 2014 | 996 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2008 | 68 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 20 | 0.020 |
Why?
| | Isoleucine | 1 | 2008 | 15 | 0.020 |
Why?
| | Blotting, Southern | 1 | 2008 | 73 | 0.020 |
Why?
| | Threonine | 1 | 2008 | 47 | 0.020 |
Why?
| | Laparoscopy | 1 | 2012 | 466 | 0.020 |
Why?
| | Oxygen | 1 | 2013 | 931 | 0.020 |
Why?
| | Monte Carlo Method | 1 | 2008 | 148 | 0.020 |
Why?
| | Antirheumatic Agents | 1 | 2010 | 293 | 0.020 |
Why?
| | Dimerization | 1 | 2008 | 199 | 0.020 |
Why?
| | Myosins | 1 | 2008 | 135 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 5742 | 0.020 |
Why?
| | Sirolimus | 1 | 2009 | 276 | 0.020 |
Why?
| | Respiratory Insufficiency | 1 | 2010 | 318 | 0.020 |
Why?
| | Recombinant Fusion Proteins | 1 | 2009 | 665 | 0.020 |
Why?
| | Cell Death | 1 | 2008 | 374 | 0.020 |
Why?
| | Stress, Physiological | 1 | 2010 | 443 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2009 | 430 | 0.020 |
Why?
| | Chronic Disease | 1 | 2012 | 1793 | 0.020 |
Why?
| | Connectin | 1 | 2006 | 33 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2014 | 2475 | 0.020 |
Why?
| | Guided Tissue Regeneration, Periodontal | 1 | 2006 | 1 | 0.020 |
Why?
| | Organ Specificity | 1 | 2007 | 305 | 0.020 |
Why?
| | Alveolar Bone Loss | 1 | 2006 | 9 | 0.020 |
Why?
| | Calcium Phosphates | 1 | 2006 | 27 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2181 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2007 | 156 | 0.020 |
Why?
| | Bone Substitutes | 1 | 2006 | 28 | 0.020 |
Why?
| | Genetic Engineering | 1 | 2006 | 93 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2006 | 332 | 0.020 |
Why?
| | Physical Conditioning, Animal | 1 | 2008 | 257 | 0.010 |
Why?
| | Muscles | 1 | 2006 | 326 | 0.010 |
Why?
| | Models, Genetic | 1 | 2008 | 600 | 0.010 |
Why?
| | Caveolins | 1 | 2004 | 6 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2013 | 2833 | 0.010 |
Why?
| | Periplasm | 1 | 2004 | 13 | 0.010 |
Why?
| | Fluorescent Antibody Technique, Indirect | 1 | 2004 | 51 | 0.010 |
Why?
| | HT29 Cells | 1 | 2004 | 41 | 0.010 |
Why?
| | Caveolin 1 | 1 | 2004 | 20 | 0.010 |
Why?
| | Membrane Microdomains | 1 | 2004 | 32 | 0.010 |
Why?
| | Specimen Handling | 1 | 2006 | 183 | 0.010 |
Why?
| | Promoter Regions, Genetic | 1 | 2009 | 1250 | 0.010 |
Why?
| | Methylprednisolone | 1 | 2004 | 86 | 0.010 |
Why?
| | Antibodies, Viral | 1 | 2008 | 625 | 0.010 |
Why?
| | Regeneration | 1 | 2006 | 197 | 0.010 |
Why?
| | Papio | 1 | 2004 | 94 | 0.010 |
Why?
| | Virulence | 1 | 2004 | 267 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1759 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2006 | 545 | 0.010 |
Why?
| | Muscle Contraction | 1 | 2006 | 424 | 0.010 |
Why?
| | Cowpox virus | 1 | 2002 | 1 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 2002 | 67 | 0.010 |
Why?
| | Drug Delivery Systems | 1 | 2006 | 365 | 0.010 |
Why?
| | Vaccinia virus | 1 | 2002 | 43 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2009 | 1457 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2008 | 847 | 0.010 |
Why?
| | Immunoglobulin A | 1 | 2004 | 211 | 0.010 |
Why?
| | DNA-Binding Proteins | 1 | 2009 | 1502 | 0.010 |
Why?
| | Peptide Fragments | 1 | 2006 | 706 | 0.010 |
Why?
| | Protein Binding | 1 | 2008 | 2224 | 0.010 |
Why?
| | Gene Expression | 1 | 2007 | 1502 | 0.010 |
Why?
| | Public Health | 1 | 2006 | 588 | 0.010 |
Why?
| | Viral Proteins | 1 | 2002 | 342 | 0.010 |
Why?
| | Communication | 1 | 2006 | 879 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2004 | 594 | 0.010 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 890 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2139 | 0.010 |
Why?
| | Disease Progression | 1 | 2006 | 2757 | 0.010 |
Why?
| | Algorithms | 1 | 2006 | 1704 | 0.010 |
Why?
| | Incidence | 1 | 2004 | 2804 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6828 | 0.010 |
Why?
| | Bacteria | 1 | 2004 | 858 | 0.010 |
Why?
|
|
Miller's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|